- Home
- TDS vs PCVX Comparison
TDS vs PCVX Comparison
Compare TDS & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDS | PCVX |
|---|---|---|
| Founded | 1968 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.1B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TDS | PCVX |
|---|---|---|
| Price | $43.95 | $58.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $53.33 | ★ $98.33 |
| AVG Volume (30 Days) | 649.7K | ★ 1.1M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.05 | N/A |
| Revenue Next Year | $1.72 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.07 | $28.09 |
| 52 Week High | $47.80 | $65.00 |
Technical Indicators
Market Signals| Indicator | TDS | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 57.05 |
| Support Level | $43.02 | $42.30 |
| Resistance Level | $45.02 | $58.95 |
| Average True Range (ATR) | 1.27 | 2.33 |
| MACD | 0.07 | 0.16 |
| Stochastic Oscillator | 95.89 | 81.44 |
Price Performance
Historical ComparisonAbout TDS Telephone and Data Systems Inc.
Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.